Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 01:20PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

Great. Thanks for joining us. I'm Terence Flynn, U.S. biopharma analyst. We're going to take a moment of silence now in memory of those we lost on September 11.

Okay, thank you for joining us, everybody. I'm really pleased to have Regeneron joining us this morning. Before we get started, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

Today, from the company, we have Marion McCourt, who is Head of Commercial; and Ryan Crowe, who is Head of Investor Relations. But thank you both so much for joining us, really appreciate the time today.

Questions and Answers:

Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

I thought maybe we'd start off with a high-level question. Obviously, IRA is one of the other topics that's top of mind for folks here. So maybe, Ryan, this is probably best for you and, Marion, if you
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot